The Latest Breaking News from Sanofi

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Good news for Americans with diabetes as Sanofi becomes the third major insulin manufacturer to cap costs at per month, reducing financial strain and i...

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. Thus, it would be prudent to buy pharma stocks, Sanofi (SNY), Johnson & Johnson (JNJ) and AstraZeneca PLC (AZN). Read on.

Hospitals were overwhelmed last winter by a surge in pediatric cases of RSV. Now a new monoclonal antibody shot could help, but price and supply issues are causing delays in getting it to infants.

A new shot for infants against RSV is in short supply, and U.S. health officials are telling doctors they should prioritize giving the drug to babies at the highest risk of severe disease

The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on.

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products